1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | JurkatE6-1; Jurkat E6-1; Jurkat, Clone E6-1; Jurkat Clone E6-1; Jurkat (clone E6-1); JURKAT E-6.1; JURKAT E-61; Jurkat-CloneE61; Jurkat-E6; Jurkat E6; J.E6-1; E6-1 |
| Species | Human |
| Cat.No | ABC-TC0482 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphocytes Cell Lines |
Jurkat, Clone E6-1 is a human acute T-cell leukemia cell line originally established from the peripheral blood of a 14-year-old male patient with T-cell lymphoblastic leukemia. This suspension-growing lymphoblast-like cell line exhibits rapid proliferation. Cytogenetic analysis reveals a pseudodiploid karyotype (modal chromosome number 46) with recurrent abnormalities including deletions in chromosomes 2p21-p23 and 18p11.2, alongside mutations such as the TEL-JAK2 fusion gene and a frameshift mutation in Syk kinase that abolishes protein expression. The cells express CD3 surface markers and demonstrate interleukin-2 (IL-2) production. While primarily utilized for in vitro research, this cell line has been employed in subcutaneous xenograft models of leukemia.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Jurkat, Clone E6-1 cells are used to investigate T-cell receptor signaling pathways, including CD3/CD28 co-stimulation and calcium-dependent NFAT activation. These cells serve as models for studying HIV latency mechanisms through engineered HIV-infected clones, enabling evaluation of viral reactivation and antiretroviral drug efficacy. The cell line is employed in preclinical screening of kinase inhibitors targeting JAK/STAT signaling abnormalities caused by TEL-JAK2 fusions. In immunotherapy development, Jurkat E6-1 derivatives modified with chimeric antigen receptors (CARs) test cytotoxic T-cell activation protocols. Xenograft models using this line assess leukemia progression in immunodeficient mice.
